Insulin-like growth factor-binding protein-3 and -5 (IGFBP-3 and -5) have been shown to bind insulin-like growth factor-I and -II (IGF-I and -II) with high affinity. Previous studies have proposed that the N-terminal region of IGFBP-5 contains a hydrophobic patch between residues 49 and 74 that is required for high affinity binding. These studies were undertaken to determine if mutagenesis of several of these residues resulted in a reduction of the affinity of IGFBP-3 and -5 for IGF-I. Substitutions for residues 68, 69, 70, 73, and 74 in IGFBP-5 (changing one charged residue, Lys68, to a neutral one and the four hydrophobic residues to nonhydrophobic residues) resulted in an ~1000-fold reduction in the affinity of IGFBP-5 for IGF-I. Substitutions for homologous residues in IGFBP-3 also resulted in a >1000-fold reduction in affinity. The physiologic consequence of this reduction was that IGFBP-3 and -5 became very weak inhibitors of IGF-I-stimulated cell migration and DNA synthesis. Likewise, the ability of IGFBP-5 to inhibit IGF-I-stimulated receptor phosphorylation was attenuated. These changes did not appear to be because of alterations in protein folding induced by mutagenesis, because the IGFBP-5 mutant was fully susceptible to proteolytic cleavage by a specific IGFBP-3 protease. In summary, residues 68, 69, 70, 73, and 74 in IGFBP-5 appear to be critical for high affinity binding to IGF-I. Homologous residues in IGFBP-3 are also required, suggesting that they form a similar binding pocket and that for both proteins these residues form an important component of the core binding site. The availability of these mutants will make it possible to determine if there are direct, non-IGF-I-dependent effects of IGFBP-3 and -5 on cellular physiologic processes in cell types that secrete IGF-I.

The insulin-like growth factor-binding proteins (IGFBPs) are known to have high affinity for IGF-I and -II, and in most cases, the affinity of the intact proteins is greater than the IGF-I receptor (1). Therefore, IGFBPs are capable of regulating the equilibrium distribution of IGF-I and -II between that bound to the receptor and that bound to the binding proteins in solution or in extracellular matrix and on cell surfaces (2, 3). Because IGFBPs generally exist in a molar excess over IGF-I in extracellular fluids, they potentially control the amount of receptor stimulation that occurs under equilibrium conditions (4). Several investigators have been interested in the domains of the IGFBPs that mediate IGF-I and -II binding. In general, this has been analyzed by determining the affinities of various IGFBP fragments (5). Both N- and C-terminal fragments of IGFBP-3 and -5 have been shown to have detectable binding affinity for IGF-I and -II, although generally their affinities are reduced between 100- and 1000-fold compared with the native proteins (5–10). Affinities of the IGFBPs can also be modified by post-translational modifications other than proteolysis, including glycosylation and phosphorylation, but in general these studies have not led to hypotheses regarding the location of the IGF-I binding site (11–12). In addition, three-dimensional structural analysis of IGF-I and -II has enabled investigators to make predictions about the regions of IGFBPs that are likely to interact with hydrophobic and charged regions within the IGFs themselves (13–19).

The IGFBPs share a common domain organization. The highest conservation is found in the N terminus of the protein (i.e. the first 80 amino acids) in the C-terminal region. Twelve conserved cysteines are found in the N-terminal domain and six in the C-terminal domain. The central regions are much less well conserved and do not contain cysteines, with the exception of IGFBP-4.

It has been proposed, based on fragment analysis, that the high affinity binding site for IGFs is located in the N-terminal domain, although studies with IGFBP-2 and -3 have suggested that C-terminal domain binding components are also present (5, 20, 21). A recent study by Kalus et al. (6) using solution NMR demonstrated that the N-terminal domain of IGFBP-5 contained one high affinity site for IGF-I and -II binding. These investigators further determined that a hydrophobic patch (residues 49, 50, 69, 73, and 74) and a critical charged residue, lysine 68, existed within this motif that probably accounted for the binding of this fragment. Because the study by Kalus et al. (6) did not use the intact protein, these studies were conducted to determine if altering these residues by in vitro mutagenesis in the intact form of IGFBP-5 would result in reduced affinity for IGF-I and therefore whether the model of the binding pocket formulated using data obtained with the IGFBP-5 fragment was also valid for the intact protein. We further tested...
IGF Binding Site in IGFBP-3 and -5

the importance of these specific residues and the applicability of the model by making homologous substitutions in IGFBP-3.

EXPERIMENTAL PROCEDURES

Materials—Recombinant human IGF-I was a gift from Genentech (South San Francisco, CA). Des-1–3 IGF-I was a gift from Monsanto, Inc. (St. Louis, MO). Human dermal fibroblasts (GM-10A) were purchased from Coriell Institute (Camden, NJ). Chinese hamster ovary K1 cells were obtained from the Lineberger Comprehensive Cancer Tissue Culture Facility (Chapel Hill, NC). The mammalian expression vector pcDNA 3.1 and TOPO TA cloning kit were obtained from Invitrogen Corporation (Carlsbad, CA). Strataclean resin was purchased from Stratagene (La Jolla, CA). The antisera that had been prepared using human IGFBP-3 and IGFBP-5 have been described previously (22). The antiphosphotyrosine antibody (PY99) and an antibody against the β subunit of the IGF-I receptor (C-20) were obtained from Santa Cruz Biotechnology Co. (Santa Cruz, CA).

Construction of Plasmids That Express Native and Mutant Forms of IGFBPs—The preparation of expression vector pcRcRSV-IGFBP-5 that contains a full-length human IGFBP-5 DNA has been described previously (23). Mutant IGFBP-5 cDNA was prepared in pcRcRSV-IGFBP-5 as described previously (23). Single-stranded phagemid-DNA was generated from pNUT-IGFBP-5, and mutations were introduced by in vitro mutagenic oligonucleotides as substrates for antisense DNA synthesis. The following complementary oligonucleotide was used to mutate Lys30, Pro36, Leu37, and Leu43 to Asn, Gln, Gln, and Gly, respectively.

A human IGFBP-3 DNA was cloned into pcDNA 3.1 vector (pcDNA3-IGFBP-3) from pNUT-IGFBP-3 that contained a full-length human IGFBP-3 cDNA (22). Arg30, Pro36, Leu37, and Leu43 of IGFBP-3 were mutated to Ser, Ala, Ser, Gln, and Gly using oligonucleotides that contained the desired substitutions and restriction enzyme cleavage sites as primers for PCR. The 5′-half of the IGFBP-3 sequence that included the start codon of IGFBP-3 to nucleotide 338 was amplified using a 5′-primer that had the wild type sequence and a 3′-primer that had the substituted sequence and an EcoRV site (primer A). The PCR product of the IGFBP-3 sequence that spans nucleotides 286 to the 3′-end of IGFBP-3 was amplified using a 5′-primer that contained the mutated sequence and a Msc site and a 3′-primer that contained the wild type sequence (primer B). PCR was performed using pCDNA3-1-IGFBP-3 as a template using an Advantage PCR kit (CLONTECH, Palo Alto, CA). The PCR products were then purified by adding 5 μl of Stratagene resin followed by centrifugation. The supercoiled plasmid DNA was cut with Hind III and EcoRI and purified by ethanol precipitation. The plasmid DNA was precipitated with methanol and probed with antisera against human IGFBP-3 or -5 and antisera. Purity was proven by SDS-polyacrylamide gel electrophoresis with silver staining, and the amount of each protein was determined.

IGF-I Binding Assay—The affinity of native and mutant IGFBPs for [125I]IGF-I was determined as described previously (19). Briefly, 20,000 cpm of [125I]IGF-I was incubated with 0–100 ng of native or mutant IGFBPs in 0.25 ml of 0.1 M Hepes, 44 mM sodium phosphate, 0.1% Triton X-100, 0.1% BSA, 0.2% sodium azide, pH 6.0, for 1 h at room temperature. Bound and free IGF-I were separated by precipitation using 12% polyethylene glycol (M, 8000–12,0000). Scatchard analysis was also performed. Duplicates were incubated with increasing concentrations of IGF-I (0.053–133 nM) and bound and free IGF-I were separated by precipitation using 12% polyethylene glycol (M, 8000–12,000) as described previously (27). The data were then analyzed according to the method of Scatchard, and the results that were obtained with native IGFBP-3 or -5 were compared with those obtained using the mutants.

Blotting—Ten or forty nanograms of IGFBPs were mixed with Laemmli sample buffer in the absence of a reducing agent and incubated at 65 °C for 10 min. The samples were then separated on a 12.5% SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride membrane as described previously (24). The membrane was blocked with 10% Tris, 150 mM NaCl, 0.5 mg/ml sodium azide, pH 7.4, plus 3% Nonidet P-40 for 15 min and then washed with this buffer containing 0.1% BSA for 2 h followed by this buffer plus 0.1% Tween 20 for 10 min at 4 °C. The membrane was then incubated with 100,000 cpm/ml [125I]IGF-I in this buffer (total volume 4 cc) containing 1% BSA and 0.1% Tween 20 for 20 h at 4 °C. The membrane was washed three times with this buffer containing 0.1% Tween 20 and three times with this buffer alone for 15 min, each with gentle agitation at 4 °C. The membrane was dried and exposed to x-ray film (Kodak XAR) to visualize the binding of [125I]-IGF-I. The same membranes were rehybridized with methanol and probed with antisera against human IGFBP-3 or human IGFBP-5, as described below.

Protolyisis of Native/Mutant IGFBP-5 by the IGFBP-5-specific Protease—Serum-free conditioned medium was obtained from human dermal fibroblasts (GM10A cells). These cells have been shown to secrete an IGFBP-5-specific protease (28). Native or mutant IGFBP-5, 150 ng, was incubated with 50 μl of conditioned medium in 60 μl Tris and 4 mM CaCl2 with or without 200 ng of IGF-I in a total volume of 60 μl overnight at 37 °C. The reaction mixture was then analyzed by immunoblotting as described below.

Immunoblotting—The samples were separated on SDS-polyacrylamide gel (8% for analysis of IGF-I receptor and 12.5% for analysis of IGFBP-3 and IGFBP-5) and transferred onto polyvinylidene difluoride membrane, as described previously (24). For IGF-I receptor analysis, the membrane was probed with a 1:1000 dilution of a murine antibody or a 1:1000 dilution of IGFBP-5 antibody, as described previously. For IGFBP-3 and IGFBP-5, the membrane was washed three times with this buffer containing 0.1% Tween 20 and then incubated with a 1:1000 dilution of IGFBP-3 antibody or a 1:1000 dilution of IGFBP-5 antibody, as described previously (24). The results were quantified by scanning densitometry (Hoefer Scientific, San Francisco, CA). One signal intensity was analyzed using N.I.H. Image.

1H-Thymidine Incorporation INTO DNA—To determine the effect of IGFBP-3 and -5 and the mutants on [3H]thymidine incorporation into DNA, increasing concentrations of mutant and wild type IGFBP-3 (25–700 ng/ml) or IGFBP-5 (250–7000 ng/ml) were added in the presence of 10 ng/ml of IGF-I. Quiescent, porcine aortic smooth muscle cells (pSMC) were isolated as described previously (23, 30). They were plated at high cell densities at 5000 cells/cm² in DMEM supplemented with 10% fetal bovine serum. After 5 days the media were aspirated, and 0.2 ml of fresh media containing 0.2% human platelet-poor plasma and test concentrations of IGFBP-3 or -5 plus IGF-I and 0.5 μCi/well of [3H]thymidine (specific activity 33 Ci/mmol) was added. After 36 h, the amount of [3H]thymidine incorporated into DNA was determined after extracting the DNA as described previously (24).

Smooth Muscle Cell Migration—pSMC monolayers were grown to confluency in 6-well plates in DMEM supplemented with 10% fetal bovine serum. Confluent monolayers were wounded with a single-edged razor blade as described previously (30). Test concentrations of IGF-I and IGFBP-3 and -5 and their mutants were added in DMEM containing 0.2% fetal bovine serum. After 72 h, the number of cells migrating across the line of wounding were counted, as described previously (30). Cells were fixed and stained with methylene blue prior to counting. The
RESULTS

Synthesis of Mutant Forms of IGFBP-3 and -5 That Have Reduced Affinity for IGF-I—Because the prior NMR study predicted that hydrophobic residues between Val149 and Leu250 of IGFBP-5 formed the core of the IGF binding site, five of the eight residues in that region that had been predicted to form the binding pocket (i.e., Lys65, Pro95, Leu96, Leu113, and Leu124) were mutated to Asn, Gln, Gln, Gln, and Gln, respectively (13). Scatchard analysis, using the purified protein, showed that mutant IGFBP-5 had a $K_d$ of $1000 \text{ nM}$, whereas native IGFBP-5 had a $K_d$ of $56 \text{ nM}$. A mutant form of IGFBP-3 that had substitutions for homologous residues was created by changing Arg82, Pro92, Leu111, Leu112, and Leu120 to Ser, Ala, Ser, Gln, and Gly, respectively. Native IGFBP-3 had a $K_d$ of $69 \text{ nM}$, whereas the mutant had a $K_d$ of $930 \text{ nM}$. Thus, for both mutants the affinity for IGF-I was reduced >1000-fold. When the ability of increasing concentrations of mutant IGFBP-3 to bind $^{125}$I-IGF-I was studied, a significant increase in binding was not detected until 400 ng/ml was added. In contrast, a significant increase in $^{125}$I-IGF-I binding was noted at 1.0 ng/ml when native IGFBP-3 was used (Fig. 1A). Similar results were obtained for mutant and wild type IGFBP-5, and concentrations of either mutant below 100 ng showed no significant increase in binding compared with controls that contained no IGFBP-5 (Fig. 1B).

The inability of both of the mutants to bind to $^{125}$I-IGF-I was confirmed by Western ligand blotting. Neither 10 ng nor 40 ng of mutant IGFBP-3 and IGFBP-5 showed detectable binding. In contrast, both wild type proteins were easily visualized (Fig. 2A). When the same membrane was probed with antisera against IGFBP-3 and IGFBP-5, it was shown that comparable amounts of native and mutant IGFBPs were adherent to the membrane (Fig. 2B).

IGF-I Failed to Protect the Mutant Form of IGFBP-5 from Proteolysis by the IGFBP-5 Protease—Native IGFBP-5 is cleaved by a serine protease that is released by cultured human fibroblasts (26). Previous studies have shown that incubation of IGF-I with IGFBP-5 partially protects it from degradation by this protease (20, 26). Because mutant IGFBP-5 is unable to bind IGF-I, we determined whether it was protected from proteolysis when incubated with the IGFBP-5-specific protease in the presence of IGF-I. After an overnight incubation, native IGFBP-5 was degraded and yielded a predominant 22-kDa fragment (Fig. 3, lane 1). Inclusion of 100 ng of IGF-I with native IGFBP-5 decreased proteolysis (Fig. 3, lane 2). When the experiment was repeated three times, scanning densitometry showed that the intensities of the intact native IGFBP-5 band was reduced by $55 \pm 7\%$ and in the presence of IGF-I by $24 \pm 13\%$ ($p < 0.05$). In contrast, the mutant IGFBP-5 band intensity was reduced by $48 \pm 8\%$ without IGF-I and by $57 \pm 11\%$ with IGF-I (p, N.S.) (Fig. 3, lanes 5 and 6). Therefore, binding of IGF-I to IGFBP-5 appears to be necessary for IGF-I to protect IGFBP-5 from proteolysis by this protease.

Native IGFBP-5 Inhibited IGF-I-stimulated Phosphorylation of IGF-I Receptor, whereas the Mutant IGFBP-5 Had Little Effect—The addition of intact IGFBP-5 to the culture medium has been shown to inhibit IGF-I-stimulated phosphorylation of the IGF-I receptor (6, 24). Therefore, we determined whether the mutant IGFBP-5 had any effect on IGF-I receptor phosphorylation. Incubation of pSMC with 100 ng/ml IGF-I resulted in the stimulation of tyrosine phosphorylation of the IGFBP-I receptor (Fig. 4). The addition of 1 ng/ml native IGFBP-5 to the IGF-I-stimulated cultures prevented phosphorylation of IGF-I receptor completely. On the other hand, the same amount of the mutant IGFBP-5 did not alter the IGF-I receptor phosphorylation stimulation by IGF-I. The stimulation of phosphorylation of the IGF-I receptor by des-1–3-IGF-I that binds IGFBP-5 with very low affinity was not affected significantly by the presence of native IGFBP-5 nor the mutant IGFBP-5 (data not shown). The incubation of cells with either native or mutant IGFBP-5 in the absence of IGF-I did not stimulate phosphorylation of IGF-I receptors (data not shown).

Migration—IGF-I is a potent stimulus of cell migration (24, 30). This IGF-I action was also decreased by co-incubation of pSMC with native IGFBP-5, but not with the mutant IGFBP-5. 50 ng/ml IGF-I-stimulated pSMC migration $121 \pm 33\%$ over control and the addition of 2.0 ng/ml of native IGFBP-5 decreased this response to a $58 \pm 16\%$ increase over control (Table I). In contrast, in the presence of 2.0 ng/ml mutant IGFBP-5, migration was increased to $115 \pm 22\%$ over control, and this was not different than the cultures exposed to IGF-I alone. Native IGFBP-3 also inhibited the IGF-I-induced migration of pSMC, but the IGFBP-3 mutant had little effect. 50 ng/ml IGF-I increased the migration of pSMC to 114 $\pm 22\%$ over control, and 500 ng/ml of native IGFBP-3 decreased the response to a $2 \pm 11\%$ increase. When the IGFBP-3 mutant was added with IGF-I, migration was increased $113 \pm 18\%$ over control (Table I).

$^{3[H]}$Thymidine Incorporation—A molar excess of IGFBP-3 or -5 can inhibit the ability of IGF-I to stimulate DNA synthesis (24). Therefore, when molar ratios of 1.12:1, 2.25:1, and 9:1 of wild type and mutant IGFBP-3 to IGF-I were added to quiescent pSMC cultures, the 4.3-fold increase in $^{3[H]}$thymidine incorporation that was stimulated by IGF-I was attenuated $84 \pm 8, 77 \pm 6, $ and $85 \pm 8\%$, respectively ($p < 0.001$ compared with IGF-I alone, mean of three experiments) (Fig. 5A). In contrast, the IGFBP-3 mutant had no effect on the response to IGF-I. When IGFBP-3 was used adding ratios of 2.9:1, 5.8:1, and 23:1, the $^{3[H]}$thymidine incorporation response to IGF-I was inhibited by $88 \pm 5, 94 \pm 4, $ and $98 \pm 7\%$, respectively ($p < 0.001$ compared with IGF-I alone) (Fig. 5B). The mutant IGFBP-5 had no effect.

DISCUSSION

These studies definitively demonstrate that a specific group of hydrophobic amino acids within the N-terminal one-third of IGFBP-3 and -5 is essential for IGF-I binding. Previous studies using solution NMR spectroscopy had determined that a fragment of IGFBP-5 containing this region of the protein folded in such a way that these residues formed a hydrophobic patch that was probably an important IGF-I binding site (6). Similarly, other investigators had reported that N-terminal fragments of IGFBP-2, -3, and -4 could bind to IGF-I (7–9, 25, 31, 32). Prior studies had to be conducted with IGFBP fragments,
because when the intact proteins were used to make similar
determinations, an unacceptable level of aggregation obscured
the ability to make this determination by NMR spectroscopy.
However, the IGFBP fragments that have been analyzed pre-
viously have a significantly reduced affinity for IGF-I. There-
fore to determine if the putative solution structure of the bind-
ing epitope of the fragment would behave in a similar manner
within the whole protein, we chose to selectively alter five of
the eight residues of IGFBP-5 that were proposed to form this
hydrophobic patch.

The strategy to use these five residues rather than all eight
was dictated by the fact that the three other residues, at posi-
tions 49, 50, and 62, are separated from this pocket by several
residues. Additionally, making a smaller number of substitu-
tions would make it less likely that the effect of the substitu-
tions was due solely to an alteration in the tertiary structure of
the protein. This IGFBP-5 mutant had a >1000-fold reduction
in affinity for IGF-I. Although the solution structure of IG-
FBP-3 was not determined in the prior study (6), homologous
residues are present in IGFBP-3. Therefore we chose to mutate
these homologous residues to either neutral or nonhydrophobic
residues. The effect of these substitutions on the affinity of
IGFBP-3 for IGF-I was similar to that observed with IGFBP-5
(i.e. greater than 1000-fold reduction in affinity).

Although these substitutions would have destroyed the hy-
drophobic patch as predicted from the NMR model, we cannot
exclude the possibility that other changes in tertiary structure,
such as alteration of the disulfide bonding pattern or important
folding disruptions, occurred as a result of these substitutions.
Because five substitutions were present, this is certainly a
possibility. However, we favor the idea that this series of mu-
tations disrupted the hydrophobic patch and that this is the
principle reason that binding affinity is reduced. Several ob-
servations support this conclusion. First it is based on a ratio-
nal protein folding model proposed by Kalus et al. (6). Second,
no direct cysteine substitutions were performed, and therefore

**Fig. 1.** Binding of 125I-IGF-I to na-
tive and mutant forms of IGFBP.
0.25–100 ng of native (solid line) and mu-
ant (dashed line) forms of IGFBP-3 (A) or
IGFBP-5 (B) were incubated with 125I-
IGF-I, and the radioactivity that bound to
IGFBPs was precipitated using polyethyl-
ene glycol, as described under "Experi-
mental Procedures." The radioactivity
precipitated in the absence of the IGFBPs
was subtracted as background, and the
data were expressed as a percentage of
the total isotope added that bound. The
result is the mean ± S.D. (n = 4) and is
the result of two independent experi-
ments. *, p < 0.01 compared with control
tubes that contained no binding protein.
FIG. 2. Ligand blot and immunoblot analysis of native and mutant IGFBP-3 and -5. 10 or 40 ng of native and mutant IGFBP-3 and -5 were separated on 12.5% polyacrylamide gel and transferred onto polyvinylidene difluoride membranes. The membrane was first blotted with [125I]-IGF-I (A) and then probed with anti-IGFBP-3 antibody (B, lanes 1–4) or anti-IGFBP-5 antisera (C, lanes 5–8), as described under “Experimental Procedures.” Lane 1, 40 ng of native IGFBP-3; lane 2, 10 ng of native IGFBP-3; lane 3, 40 ng of mutant IGFBP-3; lane 4, 10 ng of mutant IGFBP-3; lane 5, 40 ng of native IGFBP-5; lane 6, 10 ng of native IGFBP-5; lane 7, 40 ng of mutant IGFBP-5; lane 8, 10 ng of mutant IGFBP-5. The upper arrow denotes the position of IGFBP-3, and the lower arrow indicates the position of IGFBP-5. The figure is the representative result of three experiments that gave similar results.

FIG. 3. Proteolysis of native and mutant IGFBP-5 by the IGF-BP-5-specific protease. 150 ng of native (lanes 1–3) or mutant (lanes 4–6) IGFBP-5 was incubated for 14 h at 37 °C with fibroblast-conditioned medium that contained IGFBP-5 protease activity (lanes 1, 2, 5, and 6). IGF-I (200 ng) was added to the samples shown in lanes 2 and 6 and omitted from the samples shown in lanes 1 and 5. The samples shown in lanes 3 and 4 were not exposed to the protease but were incubated in buffer alone. The reaction mixtures were separated on 12.5% SDS-polyacrylamide gel electrophoresis and analyzed by immunoblotting using an antisera against IGFBP-5. The upper arrow denotes the position of intact IGFBP-5, and the lower arrow indicates the position of the major 22-kDa fragment. The figure is the representative result of three experiments that gave similar results.

There is no reason a priori to believe that the disulfide bonding pattern would be altered. Third, the identical substitutions in IGFBP-3 resulted in a similar attenuation in affinity, suggesting that if the effect were due solely to an alteration in tertiary structure that the identical change would have to occur in IGFBP-3, which has regions of sequence that are clearly distinct from IGFBP-5. Finally, the five substitutions are also in close physical proximity with one another, making it less likely that some other important structural determinant at a distant site in the molecule was altered. For all of these reasons, we believe that the model of Kalus et al. (6) is correct and is validated by these data as presented.

These data do not exclude the possibility of important binding determinants in the C terminus of the IGFBPs. Other laboratories have published data suggesting that fragments of IGFBP-3 or -5 containing the only C-terminal region have some affinity for IGF-I and -II (5, 21, 33). Other investigators have noted that the C-terminal region of IGFBP-2 contains an IGF-I binding site (20, 31, 34). Similarly, Bramani et al. (35) have presented data suggesting that substitutions for residues 205 and 207 in IGFBP-5 results in a major loss of affinity of this protein for IGF-I. The model of Kalus et al. (6) also proposed that the C-terminal region, although not containing a distinct high affinity site, could fold such that a critical C-terminal region interacted cooperatively with the hydrophobic bonding pocket in the N terminus. This type of interaction has also been proposed to occur in IGFBP-4 (32). Our data show only that the N-terminal binding pocket is essential for high affinity binding but do not help in determining the essentiality of the C-terminal region binding domain. Similarly, they do not exclude its possible importance in determining the binding affinity of the whole protein.

The loss of binding resulted in major functional changes in IGFBP-3 and -5 actions. These proteins have been shown to be potent inhibitors of several physiologic processes that are stimulated by IGF-I. This was confirmed with the native forms of IGFBP-3 and -5 showing that they could attenuate the IGF-I response to cell migration and stimulation of [3H]thymidine incorporation. Furthermore, we show that attenuation of IGF-I receptor-stimulated autophosphorylation, the first step in IGF-I signaling, is inhibited by wild type IGFBP-5, and the

**TABLE I**

Smooth muscle cell migration

The data are expressed as percent increase over control cultures that were exposed to 0.2% fetal bovine serum. *, p < 0.001 compared to IGF-I alone.

| Treatment                      | % increase over control |
|-------------------------------|-------------------------|
| IGF-I 50 ng/ml                | 114 ± 22                |
| IGF-BP-3 (wild type) 500 ng/ml| 6 ± 15                  |
| IGF-I 50 ng/ml + IGF-BP-3 500 ng/ml | 2 ± 11*               |
| IGFBP-3 (mutant) 500 ng/ml    | 19 ± 3                  |
| IGF-I 500 ng/ml + IGFBP-3 (mutant) 500 ng/ml | 113 ± 18             |
| IGF-I 50 ng/ml               | 121 ± 33                |
| IGF-I 50 ng/ml + IGF-BP-5 2.0 μg/ml| 58 ± 16*               |
| IGFBP-5 2.0 μg/ml            | 4 ± 12                  |
| IGF-I 50 ng/ml + IGFBP-5 (mutant) 2.0 μg/ml | 115 ± 22              |
| IGFBP-5 (mutant) 2.0 μg/ml    | 8 ± 10                  |
have direct effects on cell types that secrete IGF-I, because they will allow investigators to be able to exclude the possibility that IGF-I produced in an autocrine or paracrine manner is modulating the IGFFBP actions.

In an additional experiment, we were able to show that proteolytic cleavage of IGFBP-5 is partially inhibited by co-cubation with IGF-I. This inhibition did not occur when IGF-I was incubated with the IGFBP-5 mutant. This result has two important implications. First, it is likely that the mutant IGFBP-5 is folded correctly to expose its proteolytic cleavage site because there was no difference in the amount of proteolytic cleavage of the wild type compared with the IGFBP-5 mutant. This further supports the conclusion that substitution for the hydrophobic patch residues did not result in a major alteration in conformation of the protein. Second, it has not been possible in prior studies to determine if IGF-I was inhibiting proteolysis by binding to the protease or by binding to IGFBP-5. These data strongly suggest that binding to IGFBP-5 is required for inhibition.

In summary, these studies demonstrate definitively that a 5-residue hydrophobic patch that has been postulated to be part of the primary binding site in IGFBPs for IGF-I is necessary for high affinity binding. Alteration of these hydrophobic residues to nonhydrophobic residues results in a greater than 1000-fold reduction in affinity of IGFBP-3 and -5 for this ligand. This strongly suggests that IGFBP-3 and -5 will not bind with high affinity without these residues. The minimum number of substitutions was not determined by this study, but the findings suggest that if a fewer number of substitutions allowed nearly equal reductions in affinity, it would be possible to exclude that the tertiary structure has been altered to any great extent.

Acknowledgment—We thank George Mosley for his help in preparing the manuscript.

REFERENCES

1. Martin, J. L., and Baxter, R. C. (1999) *The IGF-I System Molecular Biology, Physiology, and Clinical Applications* (Rosenfeld, R. G., and Roberts, C. T., eds) pp. 227–257, Humana Press, Totowa, NJ
2. McCusker, R. H., Camacho-Hubner, C., Bayne, M. L., Casciere, M. A., and Clemmons, D. R. (1990) *J. Cell. Physiol.* 144, 244–253
3. Jones, J. I., Gekelman, A., Busby, W. H., and Clemmons, D. R. (1993) *J. Cell Biol.* 121, 679–687
4. McCusker, R. H., Campion, D. R., and Clemmons, D. R. (1988) *Endocrinology* 127, 1503–1510
5. Spencer, E. M., and Chan, K. (1995) *Prog. Growth Factor Res.* 9, 209–214
6. Kalus, W., Zweckstetter, M., Renner, C., Sanchez, Y., Georgescu, J., Gred, M., Demuth, D., Schmacher, B., Dony, C., Lang, K., and Iolak, T. A. (1998) *EMBO J.* 17, 6558–6572
7. Hashimoto, R., Ono, M., Fujisawa, H., Higashihashi, N., Yoshida, M., Enjoj-Kimura, T., and Sakano, K. (1997) *J. Biol. Chem.* 272, 27936–27942
8. Andreass, D. L., Loop, S. M., Zapf, J., and Keifer, M. C. (1993) *Biochem. Biophys. Res. Commun.* 195, 25–30
9. Fowlkes, J., Serra, D. M., Rosenberg, C. K., and Thrailkill, K. M. (1995) *J. Biol. Chem.* 270, 27481–27488
10. Clemmons, D. R. (1993) *Mol. Reprod. Dev.* 36, 368–375
11. Conover, C. A. (1995) *Prog. Growth Factor Res.* 6, 301–309
12. Clemmons, D. R. (1997) *Cytokine Growth Factor Rev.* 8, 45–62
13. Hobbs, D. D., Forbes, B. E., Parkinson, E. J., Francis, G. L., and Wallace, J. C. (1996) *J. Biol. Chem.* 271, 30529–30536
14. Heding, A., Gill, R., Ogawa, Y., DeMeyts, P., and Shymko, R. M. (1996) *J. Biol. Chem.* 271, 13949–13952
15. Torres, A. M., Forbes, B. E., Aplin, S. E., Wallace, J. C., Francis, J. L., and Norton R. S. (1995) *J. Mol. Biol.* 248, 385–401
16. Cooke, R. M., Harvey, T. S., and Campbell, I. D. (1991) *Biochemistry* 30, 5484–5491
17. Teresawa, H., Kohla, O., Hatanaka, H., Nagata, K., Higashihashi, N., Fujisawa, H., Sakano, K., and Inagaki, F. (1994) *EMBO J.* 13, 5590–5597
18. Bach, L. A., Heiz, S., Sakkas, K., Fujisawa, H., Perdue, J. F., and Rechler, M. M. (1993) *J. Biol. Chem.* 268, 9246–9254
19. Clemmons, D. R., Deboff, M. L., Busby, W. H., Bayne, M. L., and Casciere, M. A. (1992) *Endocrinology* 131, 890–895
20. Wang, J. F., Hampton, B., Melman, T., Burgess, W. H., and Rechler, M. M. (1988) *Biochem. Biophys. Res. Commun.* 157, 718–726
21. Ho, M. N., Delgado, C. H., Owens, G. A., and Steller, M. A. (1997) *Fertil. Steril.* 67, 870–876
22. Camacho-Hubner, C., Busby, W. H., McCusker, R. H., Wright, G., and Clemmons, D. R. (1992) *J. Biol. Chem.* 267, 11949–11956
23. Arai, T., Clarke, J. B., Parker, A., Busby, W. H., Jr., and Clemmons, D. R.
IGF Binding Site in IGFBP-3 and -5

(1996) *J. Biol. Chem.* **271**, 6099–6106

24. Imai, Y., Busby, W. H., Smith, C. E., Clarke, J. B., Garmong, A. J., Horvitz, G. D., Rees, C., and Clemmons, D. R. (1997) *J. Clin. Invest.* **100**, 2596–2605

25. Dong, Y., and Canalís, E. (1995) *Endocrinology* **136**, 2000–2007

26. Chernausek, S. D., Smith, C. E., Duffin, K. L., Busby, W. H., Wright, G., and Clemmons, D. R. (1995) *J. Biol. Chem.* **270**, 11377–11382

27. Twigg, S. M., and Baxter, R. C. (1998) *J. Biol. Chem.* **273**, 6074–6079

28. Nam, T. J., Busby, W. H., and Clemmons, D. R. (1994) *Endocrinology* **135**, 1385–1391

29. Imai, Y., Philippe, N., Sesti, G., Accili, D., and Taylor, S. I. (1997) *J. Clin. Endocrinol. Metab.* **82**, 4201–4207

30. Jones, J. I., Prevette, T., Gockerman, A., and Clemmons, D. R. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 2462–2467

31. Forbes, B. E., Turner, D., Hodge, S. J., McNeil, K. A., Furskey, G., and Wallace, J. C. (1998) *J. Biol. Chem.* **273**, 4647–4652

32. Qin, X., Strong, D. D., Baylink, D. J., and Mohan, S. (1997) *J. Biol. Chem.* **273**, 23509–23516

33. Standker, L., Wohlt, P., Mark, S., and Forssmann, W. G. (1998) *FEBS Lett.* **441**, 281–286

34. Ho, P. J., and Baxter, R. C. (1997) *Endocrinology* **138**, 3811–3818

35. Bramani, S., Song, H., Beattie, J., Tonner, E., Flint, D. J., and Allan, G. J. (1999) *J. Mol. Endocrinol.* **23**, 117–123

36. Karas, M., Danilenko, M., Fishman, D., LeRoith, D., Levy, J., and Sharoni, Y. (1997) *J. Biol. Chem.* **272**, 16514–16520

37. Valentis, B., Bhal, A., DeAngelis, T., Baserga, R., and Cohen, P. (1995) *J. Mol. Endocrinol.* **9**, 361–367

38. Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. (1993) *J. Biol. Chem.* **268**, 14964–14971